A series of cardiometabolic-related news items has been observed from Vertex, Novo Nordisk, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Altimmune initiated the pivotal Ph3 PERFORMA trial in F2-F3 MASH (view press release); Amylyx Pharmaceuticals launched a post-bariatric hypoglycemia education website (view article); and Vertex Pharmaceuticals hosted its Q2 ’26 earnings call, disclosing a new T1DM cell therapy program (view press release; slides).
A series of cardiometabolic-related news items has been observed by Pfizer, Madrigal Pharmaceuticals, Novo Nordisk, Vertex Pharmaceuticals, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed by Dexcom, Lilly, Vertex, and Biocon. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Pfizer/Metsera/Novo, Amgen, Madrigal Pharmaceuticals, Vertex Pharmaceuticals, and Hims & Hers. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Pfizer, Madrigal, Vertex, Innovent Biologics, Corbus, Esperion, and Vivani Medical. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Vertex Pharmaceuticals, Oura, Biomea Fusion, and Esperion. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, and Oramed Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
On the first day of JPM 2025, FENIX has provided coverage of presentations by major CVRM companies, including Dexcom, Amgen, Viking, Pfizer, Zealand, Medtronic, Regeneron, Vertex, Alnylam, and Cytokinetics. Roche also presented at JPM 2025 but had no meaningful discussion relating to its CVRM portfolio. Additionally, a series of CVRM-related news items have been observed: